Enanta Pharmaceuticals Inc 8-K, filed Aug 23, 2021
Enanta Pharmaceuticals Inc (ENTA)
About this 8-K
Enanta Pharmaceuticals Inc filed this 8-K on August 23, 2021, reporting on events of August 19, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
|
||
|
(Address of principal executive offices, including zip code) |
||
Registrant’s Telephone Number, Including Area Code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Election of Yujiro S. Hata to Board of Directors
The Board of Directors of Enanta Pharmaceuticals, Inc. has elected Yujiro S. Hata to serve as an independent director of the company in the class of directors whose term expires at Enanta’s 2024 annual meeting of stockholders. This election, which was effective on August 19, 2021, increases the number of directors to seven. The Board of Directors also appointed Mr. Hata to be a member of the Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors. Mr. Hata will receive the standard cash compensation for non-employee directors of Enanta, including retainer fees for Board and committee service. In addition, he received a non-statutory stock option to purchase 13,144 shares of Enanta’s Common Stock, which will vest over 36 months. Mr. Hata will also have the benefit of Enanta’s standard form of indemnification agreement for non-employee directors.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
ENANTA PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
Date: August 23, 2021 |
|
By: |
/s/ Paul J. Mellett |
|
|
|
|
Paul J. Mellett |
|
|
|
|
Senior Vice President, Finance and Administration and Chief Financial Officer |
2